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It is known that Ca-entry blockers influence Ca influx, particular-
ly via the L-type channels into variety of cells. In the CNS this results 
in blockade of neuronal hyperexcitation. There is evidence that dihy-
dropyridines influence the catecholamine neurotransmission (1). Flu-
narizine acts not only as antagonist of vasoconstrictors but as 
antagonist of histamine and prostaglandins, substances participat-
ing in the development of the pain syndrome. That's why some auth-
ors (2) use it for prophylaxis and treatment of migraine. It is 
suggested that a dysregulation of the Ca homeostasis in neurons 
plays a role in the aging process of the brain. So, Ca blockers are ex-
pected to improve some behavioral aspects of senile dementia and 
other disorders related to old age. Cacium antagonists have shown 
efficacy in various psychiatric disorders (3-5). We report herein our 
experience about treatment of psychiartic patients with DNP Ca an-
tagonist nifedipine. 
One of serious therapeutic problems in psychiatry is connected 
with tardive dyskinesia. Numerous drugs that have.been applied do 
not often lead to the needed therapeutic effect. In an open study we 
have followed-up the efficacy of nifedipine in tardive dyskinesia. 
Fifteen psychiatric patients of female sex (mean age of 68,3) 
were included in the study. Tardive dyskinesia had developed during 
continuous neuroleptic use over several years and consisted of buc-
colabial - masticatory - (12 patients) or limb movements - (3 patients). 
They were treated for 4-8 weeks with nifedipine (daily dosage of 30-
60 mg) and benzodiazepines (30 mg). The clinical method was used 
for evaluating the efficacy of the treatment. The study ended with thir-
teen patients. No change was found in 4 patients (30,8%). Orofacial 
movements reducing was observed in 7 patients (53,8%). Two pa-
tients (15,4%) (with schizophrenia and limb movements) achieved 
significant therapeutic effect. In 4 patients with schizophrenia there 
was marked improvement in alertness and sociability (30,74%). The 
results obtained from this investigation confirm for the important role 
of Ca biockers in the treatment, especially of geriatric patients suf-
fering from combined hypertension and T. D. 
Alcohol withdrawal syndrome (AWS) is a serious somatic and 
therapeutic problem. AWS has been mostly aspecifically treated until 
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now, е. g. with benzodiazepines which reduce brain hyperexcita-
bility. Therapy with Ca-antagonists could be suggested considering 
pharmacological evidences, linking AWS to alterations in Ca sensi­
tivity in the brain (6). Sixty hospitalized alcoholics of male sex were 
included in the study. Diagnosis of AWS was made according to the 
DSM-III. Patients were divided in two groups - basic and control. Pa­
tients from basic group were treated with glucose , vitamins, antibio­
tics, 30 - 60 mg of Diazepam and 40 - 60 mg of nifedipine. The 
therapeutic scheme of the control group was the same but nifedipine 
was missed. Evaluation of AWS symptoms was performed at baseline 
and after 3, 5, 7, 10, 14 and 21 days. A list of 13 symptoms was used 
to assess the incidence and the severity of AWS. We checked the 
period for suppressing the symptoms oi AWS. Significant improve­
ment of AWS was seen at evaluation on day 3, particularly in neuro­
vegetative symptoms and lasted up to the end of the study. The 
treatment was well tolerated and no side effects were observed. 
Our results confirm these of other clinical ivestigations for the 
appropriate use of Ca antagonists in the treatment of AWS. We would 
like to propose their combined application with prevailing of benzo-
diazipines when psychopathological symptoms are dominant and in 
opposite correlation when somatovegetative symptoms are more ex­
pressed. 
In conciusion we would like to emphasize that Ca blockers with 
their versatile action and insignificant side effects enrich our thera­
peutic possibilities in various psychiatric disorders. 
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